Clinical Update on Hyperlipidemia Management: Advanced Risk Assessment, New Guidelines, and New Treatments to Improve CVD Outcomes – Enduring AcademicCME Symposium

Step 1
Step 2
Step 3
Step 4
Post Test
Step 5
Step 6

Activity Title: Clinical Update on Hyperlipidemia Management: Advanced Risk Assessment, New Guidelines, and New Treatments to Improve CVD Outcomes

Early identification of risk for or development of atherosclerosis with monitoring and management of LDL-C and Lp(a) levels allows enhanced primary and secondary cardiovascular disease prevention. An increased focus on the reduction of atherosclerosis and the prevention of cardiovascular events can reduce the lifetime risk of CVD for the individual patient and also prolong length and quality of life on a population basis, given that cardiovascular disease remains the leading cause of death globally. To accomplish this goal, the healthcare community must keep pace with a growing body of research involving still-novel therapies, such as PCSK9 and siRNA, to lower LDL-C and control atherosclerosis progression. In this program our expert faculty will provide a practical analysis and discussion of recent clinical trial data for these and other newer therapeutics, highlighting management approaches that are currently available and emerging.

Internet Enduring Activity

This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, advance practice registered nurses, nurse practitioners and registered dietitians seeking to develop an expertise in clinical Lipidology.

At the Conclusion of this activity, participants should be able to:

  • Review recent advances on the atherosclerotic disease process and accurate risk assessment for elevated LDL-C and Lp(a) levels.
  • Discuss the details of the most current guidelines for lipid management to improve cardiovascular outcomes.
  • Analyze clinical trial data for lipid lowering therapies including siRNA-based treatments.
  • Develop strategies for collaboration with the healthcare team to execute individualized treatment plans to manage hyperlipidemia and reduce cardiovascular risk.
  • Become proficient at addressing barriers to care for patients with hyperlipidemia including patient education and knowledge of Merit-Based Incentive Payment System (MIPS) programs.

Statements of credit will be awarded based on the participant's completion and submission of the activity evaluation form. A statement of credit will be available for download upon completion of the online evaluation form. To receive credit, participants should complete the online course, score at least 75% on the post-test, and submit the evaluation. The deadline to claim credit is July 3, 2024.

Questions about this CME activity may be sent to the National Lipid Association’s Continuing Medical Education Department at

For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at within 4 weeks.

*IMPORTANT* Pharmacists MUST request credit before August 1, 2023. Credit requested after this date will be subject to a fee by the accreditation board.

This activity is supported by educational funding provided by Novartis.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 AMA PRA Category 1 Credits™ MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CME credit provided by the National Lipid Association
In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement
The National Lipid Association designates this enduring internet activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category I Credit™ from organizations accredited by ACCME.


Universal Activity Number – JA0007192-9999-23-026-H01-P (Application)
This Activity has been approved for 1.25 contact hour(s) (.125CEUs) of the Accreditation Council for Pharmacy Education.

The maximum number of hours awarded for this CE activity is 1.25 contact hours.

Pharmacotherapy contact hours for the Advance Practice Registered Nurses is to be determined.


Alan S. Brown, MD, MHA, MNLA
Director, Division of Cardiology
Advocate Lutheran General Hospital
Clinical Professor of Medicine
Rosalind Franklin School of Medicine and Science

Jessica M. Peña, MD, MPH, FNLA
Director, HeartHealth Program
Associate Professor of Clinical Medicine and Medicine in Clinical Radiology
Assistant Dean for Admissions
James A. Underberg, MD, MS, FNLA
Clinical Assistant Professor of Medicine NYU School of Medicine
NYU Langone Center for Cardiovascular Disease Prevention
Director, Bellevue Hospital Lipid Clinic
Nataliya Pyslar, MD, FNLA
Associate Professor of Medicine
Director of Lipid Disorders Clinic
Division of Cardiology at Cook County Health
Name Relationship Company
Alan S. Brown, MD Consultant
Amgen Esperion, Ionis, Novartis, Regneron
Amarin, Amgen, Esperion, Ionis, Regeneron
Jessica M. Peña, MD, MPH N/A Nothing to disclose.
Nataliya Pyslar, MD N/A Nothing to disclose.
Underberg, James Advisory Board
Name Relationship Company
NLA N/A The National Lipid Association Staff has nothing to disclose.
AcademicCME N/A Nothing to disclose.
John C. Elkins, DNP, MEd, NP-C, CLS, FNLA N/A Nothing to disclose.

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME. All disclosures have been reviewed and resolved at this time.

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.

The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.

Publish Date: 
Wednesday, June 28, 2023 - 15:00

This page was last updated: Jul 14, 2023